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A B S T R A C T
Background
Fetal vibroacoustic stimulation (VAS) is a simple, non-invasive technique where a device is placed on the maternal abdomen over the
region of the fetal head and sound is emitted at a predetermined level for several seconds. It is hypothesised that the resultant startle
reflex in the fetus and subsequent fetal heart rate (FHR) acceleration or transient tachycardia following VAS provide reassurance of fetal
well-being. This technique has been proposed as a tool to assess fetal well-being in the presence of a nonreassuring cardiotocographic
(CTG) trace during the first and second stages of labour.
Objectives
To evaluate the clinical effectiveness and safety of VAS in the assessment of fetal well-being during labour, compared with mock or no
stimulation for women with a singleton pregnancy exhibiting a nonreassuring FHR pattern.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (6 September 2012) and reference lists of all retrieved
articles. We sought unpublished trials and abstracts submitted to major international congresses and contacted expert informants.
Selection criteria
All published and unpublished randomised trials that compared maternal and fetal/neonatal/infant outcomes when VAS was used to
evaluate fetal status in the presence of a nonreassuring CTG trace during labour, compared with mock or no stimulation.
Data collection and analysis
Two review authors independently sought to assess for inclusion all the potential studies we identified as a result of the search strategy.
We planned to resolve any disagreement through discussion or, if required, to consult a third person. Where there was uncertainty
about a particular study, we attempted to contact study authors for additional information. However, these attempts were unsuccessful.
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Main results
The search strategies yielded six studies for consideration of inclusion. However, none of these studies fulfilled the requirements for
inclusion in this review.
Authors’ conclusions
There are currently no randomised controlled trials that address the safety and efficacy of VAS used to assess fetal well-being in labour
in the presence of a nonreassuring CTG trace. Although VAS has been proposed as a simple, non-invasive tool for assessment of fetal
well-being, there is insufficient evidence from randomised trials on which to base recommendations for use of VAS in the evaluation
of fetal well-being in labour in the presence of a nonreassuring CTG trace.
P L A I N L A N G U A G E S U M M A R Y
Vibroacoustic stimulation for fetal assessment in labour in the presence of a nonreassuring fetal heart rate trace
Vibratory and sound stimulation may help to tell how well a baby is during labour when the heart beat is showing possible concerns.
A baby’s heart rate is checked during labour to try to identify babies who are having difficulties. However, changes in the baby’s heart-
rate patterns may not always mean the baby really is having difficulties. When the heart-rate pattern is not reassuring, extra tests may
help to indicate which babies need help. Sound and vibratory stimulation (fetal vibroacoustic stimulation) is one such test. For healthy
babies it produces a positive response, and absence of this could be a sign that the baby is having difficulty. The review authors found
no randomised trials that considered vibroacoustic stimulation for this use. More research would be helpful.
B A C K G R O U N D
Description of the condition
Approximately 18% of cardiotocograph (CTG) tracings during
labour will be nonreassuring (East 2006) based on the heart rate,
variability and deceleration patterns (NICE 2007; RANZCOG
2007). Other tests may be considered to evaluate fetal well-be-
ing and potentially reduce unnecessary operative interventions,
including fetal scalp blood sampling for pH with acidosis defined
as a pH less than 7.20 (Ingemarsson 1989), or lactate estimation
with intervention indicated when values exceed 4.8 mmol/L (East
2010; Kruger 1999), the use of fetal pulse oximetry (nonreassuring
values less than 30%, (East 2007; East 2008), fetal scalp stimu-
lation (Rathore 2011), or electrocardiographic waveform analysis
(Amer-Wahlin 2002; Neilson 2012). These tests are not without
limitations, however. For example, fetal scalp blood sampling is an
invasive procedure that requires dilation of the cervix, rupture of
the membranes, and access to the fetal presenting part. An inade-
quate blood sample may be obtained due to inaccessibility of the
presenting part or an inexperienced operator (Westgren 1998). A
fetal oximetry sensor may only be applied following rupture of the
amniotic membranes and at minimum 2 cm cervical dilatation
(East 2008). A simple, non-invasive test that does not encounter
these limitations would therefore be ideal. Vibroacoustic stimula-
tion (VAS) may be one such test and has been proposed as a tool
in the assessment of fetal well-being in the presence of a nonre-
assuring CTG during the first and second stages of labour (Lin
2001).
Description of the intervention
Fetal VAS is a non-invasive technique that is inexpensive and re-
quires minimal operator expertise. A device such as an artificial
larynx or a commercially available acoustic stimulator is placed on
the maternal abdomen, over the region of the fetal head (Smith
1990). Sound is emitted at a predetermined level for several sec-
onds.
How the intervention might work
The stimulus is expected to induce a startle reflex in the fetus, with
subsequent fetal movement and fetal heart rate (FHR) acceleration
(Spencer 1991). This may align with the neurological response of
prominent pupillary dilatation following use of VAS (Cajal 2011).
2Vibroacoustic stimulation for fetal assessment in labour in the presence of a nonreassuring fetal heart rate trace (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
There may be differing responses to VAS depending on the
duration, intensity and the device used to produce the stim-
ulus (Pietrantoni 1991; Polzin 1988); gestational age (Gagnon
1987; Hoh 2009); maternal administration of magnesium sul-
phate which is associated with decreased FHR variability and re-
activity, resulting in a greater incidence of nonreactivity to VAS
(Sherer 1994); or steroid use, which has also been found to induce
a transient, but profound suppression of fetal limbmovements, af-
fecting fetal response to VAS (Rotmensch 1999).There is no stan-
dard protocol defining its optimal use. The VAS technique used
varied widely from sound frequencies ranging from 20 to 9000
Hz, sound pressure levels from 82 to 120 dB, duration of stimulus
from one to 10 seconds, and number of stimuli from one to seven
(Richards 1990).
It is hypothesised that a FHR acceleration or transient tachycardia
recorded following VAS provides reassurance of fetal well-being,
obviating the need for further intervention (Perez-Delboy 2002).
Antenatal fetal vibroacoustic stimulation
A Cochrane systematic review of VAS during the antenatal period
(Tan 2001) reported that VAS reduced the incidence of nonreas-
suring CTG and shortened testing time. Only one trial included a
comparison of palpable fetal movement following VAS or a mock
test and whether fetal movements following the test were accom-
panied by reactivity of the FHR (Marden 1997). They reported
a significant increase in fetal movements following VAS and no
difference in the number of non-reactive CTGs. The recording of
fetal movement and use of mock testing may therefore be impor-
tant considerations in future research. The review authors high-
lighted a number of areas where the randomised controlled tri-
als did not evaluate important issues such as safety and perinatal
outcome following VAS. They concluded that there was insuffi-
cient evidence from randomised controlled trials to recommend
the routine antenatal use of VAS in the assessment of fetal well-
being (Tan 2001).
Testing prenatal habituation to a vibroacoustic stimulus may play
a role in evaluating the performance of the fetal central nervous
system and therefore may be predictive of subsequent develop-
ment after birth (Gonzalez-Gonzalez 2009; Leader 1984). This
possibility is supported further in so far as deficits in central ner-
vous system volume and function restrict the response to VAS in
the anencephalic fetus (Park 2010). The use of VAS in conjunc-
tion with an abnormal biophysical profile or in high-risk preg-
nancies may provide reassurance of fetal well-being (Annunziata
2012; Papdopoulos 2007; Sood 2007).
Some researchers have raised safety concerns of the stress induced
by VAS, such as passage of urine (Zimmer 1993), FHR decel-
eration (Ingemarsson 1989), or potential cochlear damage from
increased intrauterine sound levels (Tan 2001). The risk of hear-
ing impairment has been considered from a number of angles, in-
cluding its implausibility given the decibel level changes in utero
from the stimulus (Arulkumaran 1991; Arulkumaran 1992; Smith
1990); long-term follow-up of infants exposed to VAS antenatally,
with no evidence of auditory nerve and brain stem evoked re-
sponses at two days of age (Ohel 1987); or of hearing impairment
or neurological damage at 18 months and three years (Ratcliffe
2000) or four years of age (Nyman 1992). A further study ex-
amined 28 fetuses of hearing-impaired women, those who had
previously had a baby with hearing impairment and three fetuses
with congenital rubella. A negative response to VAS correctly pre-
dicted the three fetuses who were later identified as being hearing
impaired, while those fetuses with a normal response to VAS had
normal hearing when tested both after birth and at three years of
age (Johansson 1992).
Intrapartum fetal vibroacoustic stimulation
Studies ofVASduring labour, precededby either noFHRmonitor-
ing or normal FHRpatterns, have notedFHRaccelerations follow-
ing VAS, compared to either mock or no stimulus (Anyaegbunam
1994; Marden 1997). One study suggested that the combination
ofVAS and assessment of the amniotic fluid index during the latent
phase of labour was a good predictor of the fetus’s ability to with-
stand labour (Phelan 1989). Others have addressed some safety
concerns. For example, Zimmer 1996 reported that, in women
with single, term pregnancies, in early labour at cervical dilatation
less than 4 cm, having intact membranes and a reassuring CTG,
there was no difference in the rate of meconium-stained liquor
when the membranes subsequently ruptured within an hour of
either a real or mock stimulus. Murphy 1993 allocated women
undergoing elective caesarean section to fetal VAS or no stimulus
prior to uterine incision, and reported no difference in maternal
venous, umbilical arterial or venous catecholamine or renin levels
for the two groups.
A systematic review of observational studies where VAS was fol-
lowed by fetal scalp pH estimation reported likelihood ratios and
95% confidence intervals (CI) for a positive test result, i.e. where
no FHR acceleration following stimulus predicted the presence of
fetal acidaemia, of 5.06 (CI 2.69 to 9.50) and a negative test re-
sult, i.e. where FHR acceleration predicted no acidaemia, of 0.32
(CI 0.19 to 0.55) (Skupski 2002a; Skupski 2002b). Having de-
termined this degree of diagnostic accuracy, the authors suggested
VAS was an appropriate test to evaluate fetal well-being in the
presence of a nonreassuring CTG, with a recommendation that
fetal scalp pH be estimated when the stimulus failed to elicit ac-
celeration of the FHR (Skupski 2002a; Skupski 2002b). That sys-
tematic review was designed to examine the diagnostic accuracy
of VAS, rather than to examine results from unpublished studies
or randomised controlled trials for correlation between VAS and
maternal/fetal outcomes, including mode of birth (including op-
erative birth for fetal concerns), other forms of assessment of fetal
well-being (including oxygen saturation or scalp pH/lactate val-
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ues) or to evaluate the potential safety concerns. It therefore does
not provide sufficient evidence on which to base practice.
Further studies not included in the Skupski 2002a and Skupski
2002b reviews have evaluated fetal scalp pH following VAS, with
most reporting a scalp pH greater than 7.20 following a positive
FHR response to VAS and scalp pH less than 7.20 when there
had been a negative result following VAS (Edersheim 1987; Lin
2001; Polzin 1988; Smith 1986). There were some false negatives,
where a positive result to VAS was followed by a pH greater than
7.20 (Ingemarsson 1989; Irion 1996; Lin 2001). The duration
and intensity of the stimulus are likely to have contributed to these
findings. Studies that did not observe false negative results used
a three-second stimulus (Edersheim 1987; Smith 1986) whereas
thosewith false negatives used a five-second stimulus (Ingemarsson
1989; Irion 1996). Different intensity of sound from different
models of artificial larynx may also contribute to the occurrence of
false negatives: Polzin 1988 and Lin 2001, who both reported false
negatives, used different vibroacoustic stimulators to those used
in the other studies cited. This possibility is supported by studies
that examined the FHR response to scalp stimulation during fetal
scalp blood sampling. Many fetuses exhibit an acceleration of their
heart rate following such an intense stimulus, although the pH
may be less than 7.20 (Ingemarsson 1989).
Why it is important to do this review
Fetal VAS is a simple, non-invasive technique that has the potential
to provide reassurance of fetal well-being. Because of its simplicity
and non-invasiveness, VAS has been proposed as a tool to assess
fetal well-being in the presence of a nonreassuring CTG during the
first and second stages of labour. Such an inexpensive test may be
particularly useful in primary carewhenmore sophisticated devices
and/or interventions are not readily available (Hofmeyr 1997;
Hofmeyr 1998). Since VAS is used and is perceived as convenient,
quick, and effective, it is important that scientific research supports
the use of VAS as a safe test of fetal well-being. This review will
assess the clinical effectiveness and safety of VAS used to assess
fetal well-being in labour in the presence of a nonreassuring CTG.
O B J E C T I V E S
To evaluate the effectiveness and safety of intrapartum fetal vi-
broacoustic stimulation (VAS) in the assessment of fetal well-be-
ing, compared with mock or no stimulation for women with a
singleton pregnancy exhibiting a nonreassuring cardiotocographic
(CTG) trace, considering the following hypotheses.
(i) Compared with mock or no stimulation, VAS may reduce the
number of tests performed to confirm the presence or absence of
fetal acidaemia.
(ii) Compared with mock or no stimulation, VAS may reduce the
number of tests performed to evaluate fetal well-being without
increasing the rate of fetal or neonatal acidaemia.
(iii) Compared with mock or no stimulation, VAS may reduce
the number of operative deliveries (caesarean section, vacuum,
forceps) performed for the indication of nonreassuring status.
(iv) Compared with mock or no stimulation, VAS may reduce the
number of operative deliveries (caesarean section, vacuum, for-
ceps) performed for the indication of nonreassuring status without
increasing the rate of fetal or neonatal acidaemia.
(v) Compared with mock or no stimulation, VAS may reduce the
overall number of operative deliveries (caesarean section, vacuum,
forceps).
A secondary objective of the review is to determine whether the
effectiveness and safety of intrapartum vibroacoustic stimulation
is influenced by the following:
(i) stage of labour;
(ii) gestation: 26 to 31 weeks six days, or 32 to 36 weeks six days,
or at least 37 weeks;
(iii) duration of stimulus: less than five seconds or at least five
seconds;
(iv) maternal administration of magnesium sulphate or steroids.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished individually- or cluster-ran-
domised trials that compared maternal and fetal/neonatal/infant
outcomes when VAS was used to evaluate fetal status in the pres-
ence of a nonreassuring CTG, compared with mock or no stimu-
lation. Mock stimulation is achieved by placing the vibroacoustic
device against the maternal abdomen in the same manner as for
a stimulus, but without activating the stimulus. It is important to
distinguish mock from no stimulation to facilitate ’blinding’ of the
women to treatment allocation, which may in turn influence their
report of fetal movement. Cross-over study designs are unlikely
to be relevant for this intervention and were therefore unlikely to
be identified. We planned not to include results only available in
published abstracts.
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Types of participants
Womenwith a live singleton pregnancy exhibiting a nonreassuring
CTG trace in labour.
Types of interventions
Fetal VAS versus mock or no stimulation.
Types of outcome measures
Primary outcomes
1. Caesarean section
2. Operative vaginal birth (forceps or vacuum)
3. Neonatal hypoxic ischaemic encephalopathy
4. Neonatal seizures
5. Long-term infant disability
Secondary outcomes
Fetal/neonatal/infant outcomes
1. Fetal heart rate acceleration (increase of 15 beats per minute
from baseline, sustained for minimum 15 seconds) within 60
seconds of the VAS (or mock stimulus)
2. Fetal heart rate deceleration (early, late, variable) within 60
seconds of the VAS (or mock stimulus)
3. Number of fetuses having additional tests performed to
confirm presence or absence of acidaemia (fetal scalp sampling
(e.g. pH, lactate), fetal oxygen saturation monitoring, fetal
electrocardiogram waveform analysis)
4. Number of additional tests performed per fetus to confirm
presence or absence of acidaemia (fetal scalp sampling (e.g. pH,
lactate), fetal oxygen saturation monitoring, fetal
electrocardiogram waveform analysis)
5. Fetal scalp pH less than 7.20
6. Fetal scalp lactate more than 4.8 mmol/L
7. Fetal oxygen saturation values less than 30%
8. Fetal movement the mother perceives
9. Apgar scores less than seven at five minutes
10. Umbilical arterial pH less than 7.10
11. Umbilical arterial base excess less than -12
12. Admission to neonatal intensive care unit
13. Meconium liquor
14. Length of hospital stay
15. Hearing impairment
16. Death
17. Death or hypoxic ischaemic encephalopathy
18. Death or neonatal seizures
19. Death or long-term infant disability
Maternal outcomes
1. Mode of birth: spontaneous vaginal, caesarean section,
forceps, vacuum extraction
2. Caesarean section for nonreassuring fetal status
3. Operative vaginal birth (forceps or vacuum) for
nonreassuring fetal status
4. Maternal satisfaction with fetal monitoring in labour
5. Maternal anxiety
6. Length of hospital stay
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (6
September 2012).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
EMBASE, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords. Other searches performed by the re-
view team for the previous version of the review are described in
Appendix 1.
We did not apply any language restrictions.
Searching other resources
We also performed amanual search of the references of all retrieved
articles. We sought unpublished trials and abstracts submitted to
major international congresses and contacted expert informants.
We did not apply any language restrictions.
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Data collection and analysis
For methods used in the previous published version, see Appendix
1.
Selection of studies
Two review authors (C East (CE) and N Henshall (NH)) inde-
pendently assessed for inclusion all the potential studies we iden-
tified as a result of the search strategy. We planned to resolve any
disagreement through discussion.
Data extraction and management
Wedesigned a form to extract data. For potentially eligible studies,
two review authors (CE andNH) planned to extract the data using
the agreed form. We planned to resolve any discrepancies through
discussion with a third review author (LR Leader). There were no
differences of opinion requiring resolution. We planned to enter
data into ReviewManager software (RevMan 2011) and check for
accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details. However, these attempts were unsuccessful.
Assessment of risk of bias in included studies
Two review authors (CE, NH) planned to independently assess
the risk of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We planned to resolve any disagreement by discussion.
(1) Random sequence generation (checking for possible
selection bias)
We planned to describe for each included study the method used
to generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups.
We planned to assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We planned to describe for each included study the method used
to conceal the allocation sequence and determine whether inter-
vention allocation could have been foreseen in advance of, or dur-
ing recruitment, or changed after assignment.
We planned to assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We planned to describe for each included study themethods used,
if any, to blind study participants and personnel from knowledge
of which intervention a participant received. We would have con-
sidered that studies were at low risk of bias if they were blinded,
or if we judged that the lack of blinding would be unlikely to af-
fect results. We planned to assess blinding separately for different
outcomes or classes of outcomes.
We planned to assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We planned to describe for each included study themethods used,
if any, to blind outcome assessors from knowledge of which in-
tervention a participant received. We planned to assess blinding
separately for different outcomes or classes of outcomes.
We planned to assess methods used to blind outcome assessment
as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We planned to describe for each included study, and for each out-
come or class of outcomes, the completeness of data including
attrition and exclusions from the analysis. We would have stated
whether attrition and exclusions were reported, the numbers in-
cluded in the analysis at each stage (compared with the total ran-
domised participants), reasons for attrition or exclusion where re-
ported, and whether missing data were balanced across groups or
were related to outcomes. Where sufficient information was re-
ported, or could be supplied by the trial authors, we planned to
re-include missing data in the analyses which we undertook. We
planned to assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
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(5) Selective reporting bias
We planned to describe for each included study how we investi-
gated the possibility of selective outcome reporting bias and what
we found.
We planned to assess the methods as:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review had been reported);
• high risk of bias (where not all the study’s prespecified
outcomes had been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias
We planned to describe for each included study any important
concerns we have about other possible sources of bias.
Weplanned to assesswhether each studywas free of other problems
that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We planned to make explicit judgements about whether studies
were at high risk of bias, according to the criteria given in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). With reference to (1) to (6) above, we planned to assess
the likely magnitude and direction of the bias and whether we
considered it was likely to impact on the findings. We planned
to explore the impact of the level of bias through undertaking
sensitivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we planned to present results as summary
risk ratio with 95% confidence intervals.
Continuous data
If we identify studies in the future that report continuous data, we
will use the mean difference if outcomes are measured in the same
way between trials. We will use the standardised mean difference
to combine trials that measure the same outcome, but use different
methods.
Unit of analysis issues
Cluster-randomised trials
If we had identified cluster-randomised trials, we planned to in-
clude them in the analyses along with individually-randomised
trials. If such trials are identified in the future, we will adjust their
sample sizes using the methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions using an estimate of the
intracluster correlation co-efficient (ICC) derived from the trial
(if possible), from a similar trial or from a study of a similar popu-
lation. If we use ICCs from other sources, we will report this and
conduct sensitivity analyses to investigate the effect of variation in
the ICC. If we identify both cluster-randomised trials and individ-
ually-randomised trials, we plan to synthesise the relevant infor-
mation. Wewill consider it reasonable to combine the results from
both if there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
As a cross-over trial design would be inappropriate in this clinical
setting, we planned to exclude such trials.
Dealing with missing data
For included studies, we planned to note levels of attrition. We
planned to explore the impact of including studies with high levels
of missing data in the overall assessment of treatment effect by
using sensitivity analysis.
For all outcomes, we planned to carry out analyses, as far as possi-
ble, on an intention-to-treat basis, i.e. we would have attempted to
include all participants randomised to each group in the analyses,
and analysed all participants in the group to which they were allo-
cated, regardless of whether or not they received the allocated in-
tervention. The denominator for each outcome in each trial would
have been the number randomised minus any participants whose
outcomes were known to be missing.
Assessment of heterogeneity
We planned to assess statistical heterogeneity in each meta-anal-
ysis using the T², I² and Chi² statistics. We would have regarded
heterogeneity as substantial if the I² was greater than 30% and
either the T² was greater than zero, or there was a low P value (less
than 0.10) in the Chi² test for heterogeneity.
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Assessment of reporting biases
If we had included 10 or more studies in the meta-analysis, we
planned to investigate reporting biases (such as publication bias)
using funnel plots. If we identify additional trials in the future, we
will assess funnel plot asymmetry visually, and use formal tests for
funnel plot asymmetry. For continuous outcomes, we will use the
test proposed by Egger 1997, and for dichotomous outcomes, we
will use the test proposed by Harbord 2006. If we detect asym-
metry in either of these tests or by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We planned to carry out statistical analysis using the ReviewMan-
ager software (RevMan 2011). We planned to use fixed-effect
meta-analysis for combining data where it was reasonable to as-
sume that studies were estimating the same underlying treatment
effect: i.e. where trials were examining the same intervention, and
the trials’ populations and methods were judged sufficiently sim-
ilar. If there was clinical heterogeneity sufficient to expect that
the underlying treatment effects differed between trials, or if sub-
stantial statistical heterogeneity was detected, we planned to use
random-effects meta-analysis to produce an overall summary if
an average treatment effect across trials was considered clinically
meaningful. We would have treated the random-effects summary
as the average range of possible treatment effects and we would
have discussed the clinical implications of treatment effects differ-
ing between trials. If the average treatment effect was not clinically
meaningful, we would not have combined trials.
If in future updates we use random-effects analyses, wewill present
the results as the average treatment effect with its 95% confidence
interval, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If we had identified substantial heterogeneity, we planned to in-
vestigate it using subgroup analyses and sensitivity analyses. We
would have considered whether an overall summary was meaning-
ful, and if it was, used random-effects analysis to produce it.
We planned to carry out the following subgroup analyses.
1. Stage of labour
2. Gestation: 26 to 31 weeks six days, 32 to 36 weeks six days,
at least 37 weeks
3. Duration of stimulus: less than five seconds or at least five
seconds
4. Maternal administration of magnesium sulphate or steroids
We planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2011). In future updates, if
we identify trials, we will report the results of subgroup analyses
quoting the χ2 statistic and P value, and the interaction test I²
value.
Sensitivity analysis
We planned to carry out sensitivity analysis of the primary out-
comes to explore the effect of trial quality, including studies as-
sessed as having adequate controls in place for the prevention of
potential bias.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
Results of the search
The search strategies yielded six studies for consideration of inclu-
sion. However, none of these studies met the basic inclusion crite-
ria of nonreassuring fetal heart rate (FHR) traces recorded during
labour.
Included studies
No studies were included.
Excluded studies
Three studies (Anyaegbunam 1994;Marden 1997; Zimmer 1996)
addressed a number of the other outcomes of interest, but not
for pre-recorded nonreassuring fetal status. The study by Marden
1997 appeared to include a mix of labouring and non-labouring
women presenting to the labour ward, who had the CTG trace
applied following the stimulus: the trial had been assumed to relate
to non-labour vibroacoustic stimulation (VAS) when considered
for the systematic review of antenatal VAS by Tan 2001, and we
were unsuccessful in our attempts to contact the authors for clar-
ification of this issue.
For more details on reasons for exclusion, see Characteristics of
excluded studies.
Risk of bias in included studies
No studies met the eligibility criteria for inclusion in this review.
Effects of interventions
No studies met the eligibility criteria for inclusion in this review.
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D I S C U S S I O N
Summary of main results
The search strategy yielded six studies for consideration in the
review. None of these studies met the inclusion criteria.
The need for simple, non-invasive evaluation of fetal well-being
once a nonreassuring cardiotocographic trace (CTG) has been
recorded in labour is important in attempts to reserve interven-
tion, such as operative birth, for those fetuses truly warranting it.
Current methods, including fetal scalp blood sampling, fetal elec-
trocardiograph and fetal pulse oximetry, while offering additional
and important information, are invasive, cumbersome, sometimes
of uncertain benefit and not always available or widely utilised
(Amer-Wahlin 2002; East 2008; East 2010; Ingemarsson 1989;
Westgren 1998). The diagnostic accuracy of vibroacoustic stimu-
lation (VAS) in labour has previously been evaluated (Edersheim
1987; Ingemarsson 1989; Irion 1996; Lin 2001; Polzin 1988;
Skupski 2002a; Skupski 2002b). Following from this evaluation,
randomised controlled trials could address its safety and efficacy in
the assessment of fetal well-being when the fetus has demonstrated
a nonreassuring heart-rate pattern during labour.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are currently no randomised controlled trials that address
the safety and efficacy of fetal vibroacoustic stimulation (VAS) fol-
lowing demonstration of a nonreassuring cardiotocograph (CTG)
during labour. Although VAS is a simple, non-invasive test of fetal
well-being, there is insufficient evidence from randomised trials to
show whether VAS is effective in the evaluation of fetal well-being
during labour.
Implications for research
Well conducted randomised controlled trials addressing the safety
and effectiveness of VAS during labour are required before intra-
partum VAS can be considered to have been adequately evaluated.
Outcomes of interest could include those listed in this review. The
primary outcome may be long-term neurodevelopmental disabil-
ity: however, at least in the term fetus population, it is an adverse
outcome of such low prevalence that any change would be difficult
to power without a prohibitively large sample size. An outcome
of clinical relevance may be as simple as the number of additional
tests performed to assess fetal well-being following identification
of a nonreassuring CTG, through to operative delivery rates.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anyaegbunam 1994 Women at least 37 weeks’ gestation with cephalic presentation of a singleton fetus, no heavy meconium, full
cervical dilatation and a reassuring CTG were entered into a prospective randomised observational trial. The
study group (n = 316) had an artificial larynx activated for 5 seconds above the maternal symphysis. Controls
(n = 316) did not have the instrument activated. An investigator blinded to group allocation assessed the
fetal heart rate tracing in the 5 minutes following the stimulus for (i) acceleration, (ii) acceleration followed
by deceleration and (iii) no response. There were no differences in umbilical arterial pH or Apgar score at 5
minutes. There were more fetal heart rate accelerations and accelerations followed by decelerations in the study
group than the control group (77.2% versus 12.5%, P < 0.05). Within the 3 groups of fetal heart rate response
following the stimulus in the study group, there were no significant differences in fetal growth restriction,
umbilical arterial pH or Apgar score less than 7 at 5 minutes. There were more cases of nuchal cord in the
subgroup of cases with fetal heart rate acceleration followed by deceleration, than in the other 2 fetal heart
rate response groups
This study was excluded as women were only randomised if they had a reassuring fetal heart rate pattern and
it was not an intervention study
Marden 1997 Women admitted to the labour ward with a singleton pregnancy, at 31 weeks’ gestation or greater and with
intact membranes were randomly assigned acoustic or sham stimulation, FOLLOWED by a CTG. There was
no reference to CTG prior to study entry
A subgroup analysis of women having less than 3 contractions per 10 minutes was conducted, implying that
not all women were in established labour. By inference, however, some outcomes could be determined for
those in established labour, including: 102 of 112 in the test group with a fetal heart rate acceleration following
the stimulus, compared to 96 of 104 in the sham group; nil with a fetal heart rate deceleration following either
the stimulus or sham test; and 2 of 112 women reporting fetal movement following the stimulus, compared
to 3 of 104 following the sham test
Attempts to contact the authors were unsuccessful.
Murphy 1993 Women undergoing elective caesarean section were randomly assigned to VAS (n = 25) or no stimulus (n =
23) prior to uterine incision. There was no statistical difference between maternal venous, umbilical arterial
or umbilical venous catecholamine or renin levels for the 2 groups
The study was excluded as it did not relate to nonreassuring CTG in labour
Phelan 1989 Women in the latent phase of labour (n = 400) were screened in 4 groups for subsequent development of
fetal compromise using (i) control, (ii) FAS, (iii) AFI, or (iv) FAS and AFI. Entry criteria did not include a
nonreassuring fetal heart rate tracing. The combined use of FAS andAFI gave the highest sensitivity and highest
negative predictive value of subsequent fetal compromise in labour. Data were only available in conference
abstract form and were inadequate for analysis. MEDLINE searches based on subject and each author failed
to reveal a published report of a randomised controlled trial
Richards 1988 Low-risk labouring women (n = 40) were assigned by odd or even hospital number to either a 5 second
VAS or sham stimulus. The fetal heart rate response was interpreted later by an investigator blinded to group
allocation. There was no difference in ’abnormal baseline [fetal heart rate] pattern’ in the hour preceding and
following the stimulus for the 2 groups, or of ’distress at birth’ (caesarean for distress, Apgar scores at 1 and 5
minutes, or umbilical arterial pH < 7.20). Insufficient data were provided to allow analysis of these findings.
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(Continued)
We were unable to contact the authors
Zimmer 1996 Women at term (n = 202)with a single pregnancy in vertex presentation, in early labour at cervical dilatation < 4
cm,with intact membranes and a reactive fetal heart rate tracing were assigned, according to their identification
numbers, to receive a 3 second fetal stimulus from an electrolarynx or sham stimulus. If the membranes had
not spontaneously ruptured within an hour of the stimulus, they were artificially ruptured and the amniotic
fluid checked for the presence or absence of meconium. Twenty-four of the 101 stimulated and 24 of the 101
sham tested had meconium present in the liquor
The trial was excluded from this analysis as the fetal heart rate tracing was reassuring at study entry
AFI: amniotic fluid index
CTG: cardiotocographic trace
FAS: fetal acoustic stimulation
VAS: vibroacoustic stimulation
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Methods from previously published version
Methods
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised trials that compare maternal and fetal/neonatal/infant outcomes when vibroacoustic stim-
ulation is used to evaluate fetal status in the presence of a non-reassuring cardiotocographic, compared with mock or no stimulation.
Mock stimulation would be achieved by placing the vibroacoustic device against the maternal abdomen in the same manner as for a
stimulus, but without activating the stimulus. It is important to distinguish mock from no stimulation to facilitate ’blinding’ of the
women to treatment allocation, which may in turn influence their report of fetal movement.
Types of participants
Women with a live singleton pregnancy exhibiting a non-reassuring cardiotocographic trace in labour.
Types of interventions
Fetal vibroacoustic stimulation versus mock or no stimulation.
Types of outcome measures
Primary outcomes
(1) caesarean section;
(2) operative vaginal birth (forceps or vacuum);
(3) neonatal hypoxic ischaemic encephalopathy;
(4) neonatal seizures;
(5) long-term infant disability.
Secondary outcomes
Fetal/neonatal/infant outcomes
(6) fetal heart rate acceleration (increase of 15 beats per minute from baseline, sustained for minimum 15 seconds) within 60 seconds
of the vibroacoustic stimulation (VAS) (or mock stimulus);
(7) fetal heart rate deceleration (early, late, variable) within 60 seconds of the VAS (or mock stimulus);
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(8) number of fetuses having additional tests performed to confirm presence or absence of acidaemia (fetal scalp sampling (e.g. pH,
lactate), fetal oxygen saturation monitoring, fetal electrocardiogram waveform analysis);
(9) number of additional tests performed per fetus to confirm presence or absence of acidaemia (fetal scalp sampling (e.g. pH, lactate),
fetal oxygen saturation monitoring, fetal electrocardiogram waveform analysis)
(10) fetal scalp pH less than 7.20;
(11) fetal scalp lactate more than 4.8 mmol/l;
(12) fetal oxygen saturation values less than 30%;
(13) fetal movement the mother perceives;
(14) Apgar scores less than seven at five minutes;
(15) umbilical arterial pH less than 7.10;
(16) umbilical arterial base excess less than -12;
(17) admission to neonatal intensive care unit;
(18) meconium liquor;
(19) length of hospital stay;
(20) hearing impairment;
(21) death;
(22) death or hypoxic ischaemic encephalopathy;
(23) death or neonatal seizures;
(24) death or long-term infant disability.
Maternal outcomes
(25) mode of birth: spontaneous vaginal, caesarean section, forceps, vacuum extraction;
(26) caesarean section for non-reassuring fetal status;
(27) operative vaginal birth (forceps or vacuum) for non-reassuring fetal status;
(28) maternal satisfaction with fetal monitoring in labour;
(29) maternal anxiety;
(30) length of hospital stay.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group Trials Register by contacting the Trials SearchCo-ordinator (30 September
2004).
The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co-coordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
2. monthly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major conferences;
4. weekly current awareness search of a further 37 journals.
Details of the search strategies for CENTRAL and MEDLINE (1966 to present), the list of hand searched journals and conference
proceedings, and the list of journals reviewed via the current awareness service can be found in the ’Search strategies for identification
of studies’ section within the editorial information about the Cochrane Pregnancy and Childbirth Group
We also searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 1, 2004), MEDLINE (January 1966
to May 2004), and EMBASE (January 1966 to May 2004) using the following:
(randomised controlled trial* OR randomized controlled trial* OR controlled clinical trial OR clinical trial OR single blind OR double
blind OR placebo* OR random* OR comparative study OR prospective stud*) AND (vibroacoustic OR stimul* OR acoustic) AND
(fetal OR fetus OR foetal OR foetus) AND (labour OR labor OR intrapartum).
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Searching other resources
We also performed a manual search of the references of all retrieved articles. We sought unpublished trials and abstracts submitted to
major international congresses and contacted expert informants.
We did not apply any language restrictions.
Data collection and analysis
We used the standard methods of The Cochrane Collaboration as described in the Cochrane Reviewers’ Handbook (Alderson 2004).
Two review authors (CEEast andNHenshall) assessed the trials under consideration for appropriateness of inclusion andmethodological
quality. Any differences of opinion would have been resolved by discussion with a third review author (LR Leader): there were no
differences of opinion requiring resolution. We did not undertake blinding of trial authorship and results.
Assessment of trial quality
Four major sources of potential bias and methods or avoidance of these biases were to be considered when assessing trial quality: (1)
selection bias - allocation concealment; (2) performance bias - blinding of intervention; (3) attrition bias - completeness of follow up;
(4) detection bias - blinding of outcome assessment. The quality assessment was based on a systematic assessment of the opportunity
for each of these biases to arise.
A quality rating for allocation concealment was to be assigned to each trial, using the criteria outlined in the Cochrane Reviewers’
Handbook (Alderson 2004): (A) adequate; (B) unclear; (C) inadequate; or (D) not used. We planned to assign a quality rating of (A)
yes; (B) cannot tell; or (C) no, to the other quality components (blinding of intervention, completeness of follow up and blinding of
outcome assessment).
Trials from the review with a ’B’, ’C’ or ’D’ rating for allocation concealment would have been excluded. We made an a priori decision
to also exclude trials where outcome data were unavailable for more than 20% of participants.
Data management and analysis
Wedeveloped data extraction forms that included information regarding study location, methods, participant characteristics at baseline,
details of the intervention and control group management and outcome. Two independent review authors would have extracted the
data and disagreements would have been resolved by discussion. We would have sought missing data from investigators of individual
trials as necessary in order to perform analyses on an intention-to-treat basis. We planned to undertake double data entry.
We planned to report mean differences (and 95% confidence intervals) for continuous variables. For categorical outcomes, we intended
to report the relative risk and risk difference (and 95% confidence intervals). For the meta-analysis, where possible, we planned to
report weighted mean differences (and 95% confidence intervals) for continuous variables, and the relative risk and risk difference (and
95% confidence intervals) for categorical outcomes. We intended to calculate the number needed to treat where appropriate.
We did not assess heterogeneity since there were no studies to include in the meta-analysis.
We planned to undertake a priori subgroup analyses, as data permitted, as follows:
(i) stage of labour;
(ii) gestation: 26 to 31 weeks six days, 32 to 36 weeks six days, at least 37 weeks;
(iii) duration of stimulus: less than five seconds or at least five seconds;
(iv) maternal administration of magnesium sulphate or steroids.
17Vibroacoustic stimulation for fetal assessment in labour in the presence of a nonreassuring fetal heart rate trace (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Last assessed as up-to-date: 7 September 2012.
Date Event Description
7 September 2012 New search has been performed Review updated with searches, converted to 2012 re-
view format and updated literature review. Additional
author added
7 September 2012 New citation required but conclusions have not
changed
Studies assessed and excluded. No studies fulfil the re-
quirements for inclusion in this review
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 2, 2005
Date Event Description
10 November 2008 Amended Contact details updated.
18 February 2008 Amended Converted to new review format.
31 January 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Christine East compiled the review with considerable input from Naomi Henshall, Rebecca Smyth and Leo Leader. Rosalind Lau
contributed to the updated literature review in the 2012 update. Christine East, Naomi Henshall, Leo Leader and Rebecca Smyth
examined trials for suitability of inclusion/exclusion. All review authors had input into the original protocol and read/advised on/
approved the final draft of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• Perinatal Research Centre, The University of Queensland, Royal Brisbane and Women’s Hospital, Herston, Queensland,
Australia.
External sources
• Cochrane Perinatal Team, Brisbane, Centre for Clinical Studies - Women’s and Children’s Health, Mater Hospital, South
Brisbane, Queensland, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Two aspects from the original protocol were adjusted for the 2012 review update.
1. Rosalind Lau assisted in updating the background and discussion and was added to the authorship.
2. We removed the duplication of searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and
EMBASE conducted by both the authors and the Trials Search Co-ordinator of the Cochrane Pregnancy and Childbirth Group’s
Trials Register.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acoustic Stimulation [∗methods]; Fetal Monitoring [∗methods]; Heart Rate, Fetal [physiology]; Reflex, Startle [physiology]
MeSH check words
Humans
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